Market capitalization | $219.66m |
Enterprise Value | $155.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.41 |
P/S ratio (TTM) P/S ratio | 3.41 |
P/B ratio (TTM) P/B ratio | 1.97 |
Revenue growth (TTM) Revenue growth | 9.85% |
Revenue (TTM) Revenue | $64.49m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a SOPHiA Genetics SA forecast:
6 Analysts have issued a SOPHiA Genetics SA forecast:
Sep '24 |
+/-
%
|
||
Revenue | 64 64 |
10%
10%
|
|
Gross Profit | 44 44 |
8%
8%
|
|
EBITDA | -60 -60 |
6%
6%
|
EBIT (Operating Income) EBIT | -68 -68 |
5%
5%
|
Net Profit | -71 -71 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SOPHiA GENETICS SA is a healthcare technology company, which establishes the practice of data driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.
Head office | Switzerland |
CEO | Jurgi Camblong |
Employees | 449 |
Founded | 2011 |
Website | www.sophiagenetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.